Zacks Investment Research on MSN
Will Defencath continue to aid CorMedix's top line in Q4 earnings?
CorMedix’s CRMD lead product, DefenCath (taurolidine plus heparin), is the company’s primary source of revenues. DefenCath ...
Drivers could face up to £1,000 fines and potential prosecution if they fail to report notifiable medical conditions or ...
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback